Literature DB >> 8823235

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes.

C Y Tseng1, S L Wang, M D Lai, M L Lai, J D Huang.   

Abstract

Codeine and morphine pharmacokinetics among different CYP2D6 genotypes was compared in this study. Polymerase chain reaction tests were used to determine CYP2D6 genotypes in leukocyte deoxyribonucleic acid in 32 unrelated volunteers. Based on the genotypes, subjects were categorized into three groups: homozygous C/C188 (n = 8), heterozygous C/T188 (n = 12), and homozygous T/T188 (n = 12). Each subject was given a single oral dose of 30 mg codeine phosphate tablet after overnight fasting. Plasma concentration of codeine and 24-hour urinary morphine recovery were measured with HPLC. All three genotypes of subjects showed almost identical time profiles of plasma codeine. Urinary morphine glucuronide was hydrolyzed with beta-glucuronidase. The total recovered amount of morphine and glucuronides was 4349 +/- 646, 2564 +/- 242, and 1127 +/- 164 nmol (mean +/- SEM), respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05). The significant lower amount of urinary morphine but identical codeine plasma concentration suggested a lower partial clearance of the formation of morphine from codeine in T/T188 subjects. The results suggest a future study to assess the analgesic effect of codeine in different genotypes of CYP2D6 extensive metabolizers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823235     DOI: 10.1016/S0009-9236(96)90133-2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 2.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.

Authors:  Xiujun Wu; Li Yuan; Jinliang Zuo; Jing Lv; Tao Guo
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

4.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

5.  Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.

Authors:  Junji Saruwatari; Masayuki Matsunaga; Kazuyuki Ikeda; Masashi Nakao; Kentaro Oniki; Takayuki Seo; Shuichi Mihara; Toru Marubayashi; Tetsuya Kamataki; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

6.  Ethnic differences in pain and pain management.

Authors:  Claudia M Campbell; Robert R Edwards
Journal:  Pain Manag       Date:  2012-05

Review 7.  Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.

Authors:  Sonya C Tang Girdwood; Katelyn M Rossow; Sara L Van Driest; Laura B Ramsey
Journal:  Pediatr Res       Date:  2021-04-06       Impact factor: 3.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.